NCT03542435View on ClinicalTrials.gov

Randomized, Double-Blind, Placebo-Controlled, MAD Study to Assess the Safety, Tolerability, and Pharmacokinetics of SXC 2023

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 26, 2018

Primary Completion Date

August 8, 2018

Study Completion Date

September 10, 2018

Conditions
Healthy Volunteers
Interventions
DRUG

SXC-2023

Oral capsule

DRUG

Placebo

Placebo

Trial Locations (1)

85283

Celerion, Tempe

All Listed Sponsors
lead

Promentis Pharmaceuticals, Inc.

INDUSTRY

NCT03542435 - Randomized, Double-Blind, Placebo-Controlled, MAD Study to Assess the Safety, Tolerability, and Pharmacokinetics of SXC 2023 | Biotech Hunter | Biotech Hunter